Portal de Periódicos da CAPES

Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women

2016; Massachusetts Medical Society; Volume: 375; Issue: 22 Linguagem: Inglês

10.1056/nejmoa1506110

1533-4406

Jared M. Baeten, Thesla Palanee‐Phillips, Elizabeth R. Brown, Katie Schwartz, Lydia Soto‐Torres, Vaneshree Govender, Nyaradzo Mgodi, Flavia Matovu Kiweewa, Gonasagrie Nair, Felix Mhlanga, Samantha Siva, Linda‐Gail Bekker, Nitesha Jeenarain, Zakir Gaffoor, Francis Martinson, Bonus Makanani, Arendevi Pather, Logashvari Naidoo, Marla Husnik, Barbra A. Richardson, Urvi M. Parikh, John W. Mellors, Mark A. Marzinke, Craig W. Hendrix, Ariane van der Straten, Gita Ramjee, Zvavahera M. Chirenje, Clemensia Nakabiito, Taha E. Taha, Judith Jones, Ashley J. Mayo, Rachel Scheckter, Jennifer Berthiaume, Edward Livant, Cindy Jacobson, Patrick Ndase, Rhonda White, Karen Patterson, Donna Germuga, Beth Galaska, Katherine Bunge, Devika Singh, Daniel Szydlo, Elizabeth Montgomery, Barbara Mensch, Kristine Torjesen, Cynthia I. Grossman, Nahida Chakhtoura, Annaléne Nel, Zeda Rosenberg, Ian McGowan, Sharon L. Hillier,

HIV Research and Treatment

Antiretroviral medications that are used as prophylaxis can prevent acquisition of human immunodeficiency virus type 1 (HIV-1) infection. However, in clinical trials among African women, the incidence of HIV-1 infection was not reduced, probably because of low adherence. Longer-acting methods of drug delivery, such as vaginal rings, may simplify use of antiretroviral medications and provide HIV-1 protection.